李璨,陆爽,吴君
LI Can,LU Shuang,WU Jun

• 1:贵州医科大学感染病学教研室
• 2:贵州医科大学

摘要(Abstract)：

目的:探讨丹防胶囊对小鼠非酒精性脂肪性肝纤维化的干预效果及机制。方法:30只雄性C57BL/6J小鼠均分为正常组、模型组及丹防组,正常组给予普通饮食,模型组及丹防组给予高脂饮食喂养8周建立非酒精性脂肪性肝纤维化模型;造模同时给予丹防组小鼠1.22 g/20 g丹防胶囊灌胃,另2组小鼠给予等量生理盐水灌胃,1次/d,共8周;第8周记录小鼠体质量,检测血糖、甘油三酯(TG)、胆固醇(TC)、谷丙转氨酶(ALT)、谷草转氨酶(AST)水平;第8周末麻醉处死小鼠取肝脏组织记录肝脏重量,观察组织学改变,检测TGF-β1、Smad2、α-平滑肌(α-SMA)蛋白和mRNA及Ⅳ型胶原(col-Ⅳ)mRNA表达水平。结果:与正常组比较,模型组小鼠体质量、肝脏重量、血糖、TG、TC、ALT、AST水平均显著升高(P<0.05),肝组织空泡形成明显,有大量红色脂滴蓄积、肝纤维化严重,肝脏组织TGF-β1、Smad2及α-SMA蛋白表达水平、col-ⅣmRNA表达水平均显著上升(P<0.05);与模型组比较,丹防组小鼠体质量、血糖、TG、TC水平无明显变化(P>0.05),肝脏重量、ALT及AST水平显著下降(P<0.05),肝组织空泡形成及脂滴蓄积减少,肝纤维化程度减轻,肝组织TGF-β1、Smad2、α-SMA蛋白表达水平、col-ⅣmRNA表达水平下降(P<0.05)。结论:丹防胶囊可降低非酒精性脂肪性肝纤维化肝脏重量、ALT、AST水平,其机制可能与降低肝组织中TGF-β1及Smad2的表达有关。
Objective: To investigate the effect and mechanism of Danfang capsules on non-alcoholic fatty liver disease(NAFLD) in mice. Methods: 30 male C57 BL/6 J mice were randomly divided into the normal group, the model group and Danfang group, 10 mice in each group. The normal group was fed with normal diet, and the model group with high-fat diet for 8 weeks to establish the model with NAFLD. At the same time, 1.22 g/20 g Danfang capsules were given to Danfang group, and other groups were given the same amount of normal saline once a day for 8 weeks. The body weight, the level of blood glucose, triglyceride(TG), cholesterol(TC), ALT and AST were measured during the 8 th week and mice were sacrificed under anesthesia and their livers were weighed. Liver histopathological examination was performed. The expression levels of TGF-β1, Smad2, α-SMA and col-Ⅳ mRNA in liver tissues were detected by Western blot and RT-qpcr. Results: Compared with the normal group, the body weight, liver weight, blood glucose, TG, TC, ALT, AST levels in the model group increased(all P<0.05), and the liver tissue vacuoles were significantly formed, with a large amount of red lipid accumulation and severe liver fibrosis. The liver tissue TGF-β1, Smad2,α-SMA expression and col-Ⅳ mRNA levels increased(P<0.05).Compared with the model group, there were no significant changes in body weight, blood glucose, TG and TC levels in Danfang group(P>0.05), but the liver weight, ALT and AST levels were reduced(P<0.05). The liver vacuolation, lipid droplet accumulation and degree of liver fibrosis decreased. The expression of TGF-β1, Smad2, α-SMA and col-Ⅳ mRNA levels in liver tissues decreased(P<0.05). Conclusion: Danfang capsules can reduce the liver weight, ALT and AST levels of NAFLD. The mechanism may be related to the reduction of the expression of TGF-β1 and Smad2 in liver tissues.

关键词(KeyWords)： 丹防胶囊;非酒精性脂肪性肝纤维化;TGF-β1;Smad2;Ⅳ型胶原蛋白;α-平滑肌蛋白
Danfang capsules;non-alcoholic fatty liver disease(NAFLD);TGF-β1;Smad2;col-Ⅳ;α-SMA

Abstract:

Keywords:

基金项目(Foundation): 贵阳市科技计划项目(201120419)

作者(Author): 李璨,陆爽,吴君
LI Can,LU Shuang,WU Jun

DOI: 10.19367/j.cnki.1000-2707.2020.01.012

参考文献(References)：

• [1] MARENGO A,JOUNESS R I K,BUGIANESI E,et al.Progression and natural history of nonalcoholic fatty liver disease in adults[J].Clinics in Liver Disease,2016,20:313-324.
• [2] TROVATO F M,MARTINES G F,BRISCHETTO D,et al.Fatty liver disease and lifestyle in youngsters:diet,food intake frequency,exercise,sleep shortage and fashion[J].Liver Int,2016,36:427-433.
• [3] HE Y,孙永康,苏斌,等.微小RNA-223通过靶向肝细胞中的多种炎症和致癌基因改善非酒精性脂肪性肝炎和肝癌[J].临床肝胆病杂志,2019,35(5):1097.
• [4] ZHOU X B,HUANG H.Therapeutic effect of atorvastatin combined trimetazidine on blood lipids,inflammatory factors and cardiac function in patients with coronary heart disease[J].Chin J Cardiovasc Rehabil,2016,2016:276-279.
• [5] 张征波.大黄素对非酒精性脂肪肝肝脏单纯肝脂肪变性改善作用及机制研究[D].南京:南京中医药大学,2012.
• [6] JIAN T,YU C,DING X,et al.Hepatoprotective effect of seed coat of euryale ferox extract in non-alcoholic fatty liver disease induced by high-fat diet in mice by increasing IRs-1 and inhibiting CYP2E1[J].J Oleo Sci,2019,68(6):581-589.
• [7] 李璨,陆爽,吴君,等.丹防胶囊对免疫性肝纤维化大鼠肝组织IL-33和ST2表达的影响[J].贵州医科大学学报,2019,44(4):435-440.
• [8] 黄晶晶,邓杰,徐曦,等.针刺联合减脂瘦身方治疗非酒精性脂肪性肝炎的临床研究[J].中西医结合肝病杂志,2018,28(5):288-289.
• [9] 蒋煜,胡居龙,马佳丽,等.非酒精性脂肪性肝炎大鼠模型中小檗碱抗氧化效应的观察[J].临床肝胆病杂志,2018,34(6):1273-1276.
• [10]罗利婷,牛俊奇.通过简单饮食和化学诱导构建一种可迅速进展为肝纤维化和肝癌的非酒精性脂肪性肝炎小鼠模型[J].临床肝胆病杂志,2018,34(6):1190.
• [11]马燕花,师霞,邱晓青,等.慈姑消脂丸对非酒精性脂肪性肝炎大鼠肝组织中p-JNK/p-c-Jun信号通路表达的影响[J].中药材,2017,40(12):2950-2955.
• [12]COOK N,GEIER A,SCHMID A,et al.The patient perspectives on future therapeutic options in NASH and patient needs[J].Front Med,2019,6:61.
• [13]UTZ-MELERE M,TARGA-FERREIRA C,LESSA-HORTA B,et al.Non-alcoholic fatty liver disease in children and adolescents:lifestyle change - a systematic review and meta-analysis[J].Ann Hepatol,2018,17(3):345-354.
• [14]CARO-SABIDO E A,LARROSA-HARO A.Efficacy of dietary intervention and physical activity in children and adolescents with nonalcoholic fatty liver disease associated with obesity:A scoping review[J].Rev Gastroenterol Mex,2019(19):30019-30029.
• [15]陆雷群,张叶丽,沈莹,等.肝纤维化指标对2型糖尿病合并非酒精性脂肪肝患者的早期临床诊断意义的研究[J].海南医学院学报,2019,25(13):974-978.
• [16]冷炎,杨明,欧喜燕,等.养肝解郁颗粒治疗非酒精性脂肪性肝病肝纤维化的药效学[J].中国老年学杂志,2019,39(7):1682-1684.
• [17]任桂晶,韩琳,秦少游,等.空腹C肽联合FIB-4指数对2型糖尿病合并非酒精性脂肪性肝病患者肝纤维化进展的评估价值[J].临床肝胆病杂志,2018,34(12):2582-2586.
• [18]吴紫红,宋恩峰,梅莎莎.柴归汤联合多烯磷脂酰胆碱胶囊治疗非酒精性脂肪性肝炎的临床研究[J].中西医结合肝病杂志,2019,29(2):146-148.
• [19]胡晓会,吴君,陆爽.丹防胶囊对免疫性肝纤维化大鼠的干预作用[J].中华医学杂志,2017,97(35):2783-2788.
• [20]邵作乔,刘洁薇,聂磊,等.银杏叶提取物抗纤维化机制研究述评[J].中医学报,2018,33(8):1493-1498.
• [21]李文新,车念聪,王金光,等.大黄虫丸加黄芪、水红花子对拮抗大鼠肝纤维化作用的影响[J].中华中医药杂志,2016,31(12):5320-5322.
• [22]张欣.汉防己碱对牛血清白蛋白致大鼠肝纤维化的治疗作用[J].中国肝脏病杂志(电子版),2016,8(2):29-33.
• [23]秦冬梅,张钰,李莉.具有抗肝纤维化作用的植物药研究进展[J].世界华人消化杂志,2017,25(11):958-965.
• [24]HART K M,FABRE T,SCIURBA J C,et al.Type 2 immunity is protective in metabolic disease but exacerbates NAFLD collaboratively with TGF-β[J].Sci Transl Med,2017,9(396):eaal3694.
• [25]WREE A,HOLTMANN T M,INZAUGARAT M E,et al.Novel drivers of the inflammatory response in liver injury and fibrosis[J].Semin Liver Dis,2019,39(3):275-282.
• [26]YAN X M,ZHANG L T,LI M,et al.Research progress of TGF-β1/smad signaling pathways in liver fibrosis[J].Progress in Modern Piomedicine,2016,16 (9):1778-1781.

文章评论(Comment)：